Corcept Therapeutics (CORT): Analyst Says Shares Pricing in Growth, New Launch [Yahoo! Finance]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Yahoo! Finance
On December 16, UBS analyst Ashwani Verma initiated coverage of Corcept Therapeutics Incorporated (NASDAQ:CORT) stock with a Neutral rating and $95 price target. In an investor note, the analyst cited valuation for the Neutral rating, with the shares up 64% year-to-date. Per the analyst, the stock was already pricing in both the continued growth in hypercortisolism and Corcept's new launch opportunity in platinum-resistant ovarian cancer. In early November, the company posted earnings for the third quarter of 2025, reporting earnings per share of $0.16, beating market estimates by $0.02. The revenue over the period was more than $207 million, up close to 14% compared to the revenue over the same period last year and missing analyst expectations by close to $11 million. The firm also modified 2025 revenue guidance of $800 to $850 million versus the $852 million consensus. Corcept Therapeutics Incorporated (NASDAQ:CORT) engages in the discovery and development of medications for th
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Corcept Therapeutics (NASDAQ:CORT) was upgraded by analysts at UBS Group AG to a "hold" rating.MarketBeat
- Corcept Therapeutics (NASDAQ:CORT) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- Corcept Therapeutics (NASDAQ:CORT) is now covered by analysts at UBS Group AG. They set a "neutral" rating on the stock.MarketBeat
- Assessing Corcept Therapeutics (CORT) Valuation as Relacorilant Nears Key PDUFA Decision and Analyst Optimism Builds [Yahoo! Finance]Yahoo! Finance
- Wall Street Firms Tout Corcept Therapeutics Incorporated (CORT) Prospects on Korlym Medication Prospects [Yahoo! Finance]Yahoo! Finance
CORT
Earnings
- 11/4/25 - Miss
CORT
Sec Filings
- 12/16/25 - Form 4
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- CORT's page on the SEC website